Original Publication Date: 13 July, 2016
Publication / Source: Epigenomics
Authors: Amer A Beg & Jhanelle E Gray
In one of the most significant breakthroughs in cancer treatment, recent studies have demonstrated the ability of immunotherapy involving blockade of CTLA-4 and PD-1 checkpoint receptors on T cells to induce deep and durable anti-tumor responses . PD-1 blockade is an especially promising approach with activity across multiple cancer types. However, the actual response rates are relatively low, for example, approximately 20% in unselected lung cancer patients [2,3].